Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Next Previous
Trial Profile

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riluzole (Primary)
  • Indications Social phobia
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 22 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2018 According to a Biohaven Pharmaceutical Holding Company media release, the FDA (in Nov 2018) has agreed to a modification of the trials primary endpoint, the Scale for Assessment and Rating of Ataxia (SARA) as an acceptable registrational endpoint.
    • 16 Aug 2018 According to Biohaven Pharmaceuticals media release, the company expects to present additional results from this trial at upcoming scientific meetings over the next year. Based upon these trial results, Biohaven plans to expand its glutamate modulating platform development program to include the treatment of Generalized anxiety disorder (GAD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top